Letters sent to healthcare professionals in May 2016
In May 2016, letters were sent regarding Nexplanon (etonogestrel implant) and ERWINASE.
In May 2016, letters were sent regarding:
-
Nexplanon (etonogestrel) implants have been found rarely in the vasculature and lung: an update regarding possible risks and complications regarding insertion, localisation and removal ()—see also article in this issue
-
ERWINASE: notice of special handling instructions—vials of ERWINASE from batch 174g should be used with a 5-micron filter needle ()
Article citation: Drug Safety Update vol 9 issue 11, June 2016: 4.
Updates to this page
Published 15 June 2016